Sofinnova Ventures ups the ante - again - as it closes in on $650M biotech fund
Sofinnova Ventures is close to capping off a new $650 million biotech fund. Earlier in the week the Silicon Valley-based VC group posted an SEC filing noting that it has rounded up $595.5 million for Sofinnova Venture Partners X.
This 10th fund is already well ahead of the $500 million Sofinnova raised for its 9th fund back in the summer of 2014. And it will be substantially bigger than fund 8, which raised $440 million. James Healy is the general partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
